Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?

I think we always have to do our best to ensure we have adequate NGS. If tissue-based NGS on the initial biopsy is inadequate or negative, then a liquid biopsy is a good next step. However, if the liquid biopsy is negative for driver mutations, I would have a thorough discussion with the patient abo...